

Goldendrugs Private Limited

Phone : 0294-2490411

Email : golden.drugs2012@gmail.com

Website : www.goldendrugs.in

NOTICE

NOTICE is hereby given that, the 6th Annual General Meeting of the members of GOLDEN DRUGS PRIVATE LIMITED, will be held at 10:00 A.M on Monday ,14th May, 2018 at the Registered office of the Company at #9, New Fatehpura, Udalpur, Rajasthan -313001, to transact the following business.

ORDINARY BUSINESS:

1.To receive, consider and adopt the Audited Balance Sheet and Profit and Loss Account as on 31st March, 2018 and the Reports of the Directors and the Auditors thereon;

2.To appoint Mr. Shallesh D Siroya (DIN # 00048109) as the Director of the Company.

3.To ratify the appointment of the Messrs K.N & Associates, Chartered Accountants, as statutory Auditors of the Company.

To Consider and if thought fit to pass the following resolution as an ordinary resolution.

"RESOLVED THAT pursuant to the provisions of Section 139 (1) and all applicable provisions of the Companies Act,2013 , members hereby ratifies the reappointment of Messrs K N & Associates having ICAI Firm registration No. 013495C as Statutory Auditors of the Company up to the financial year ending 31st March 2019, on such remuneration and out of pocket expenses as may be mutually agreed upon between the Board of Directors and Auditors , in connection with the audit of financial statements of the Company."

By order of the Board,
For GOLDEN DRUGS PRIVATE LIMITED

Chander Khamesara
Director

Place: Udalpur
Date: 12.04.2018

Notes:

A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY INSTEAD OF HIMSELF OR HERSELF. A PROXY NEED NOT BE A MEMBER OF THE COMPANY. PROXY FORMS IN ORDER TO BE EFFECTIVE MUST BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.



REGD OFFICE : # C-165, New Industrial Area, Madal, Udalpur - 313001, Rajasthan

C-135, M.A. Madal, Udalpur, Rajasthan, 313003

DIN # 124237R32017P1C030001



Goldendrugs Private Limited

BOARD'S REPORT

To,
The Members,

Your Directors hereby presents their sixth Annual Report on the business and operations of the Company and accounts for the Financial year ended on 31st March ,2018.

1.FINANCIAL PERFORMANCE :

As the Company has not yet commenced its commercial operations, reporting of the financial performance of the Company may not be applicable for F.Y 2017.18.

2. DIVIDEND :

As the Company has not generated any revenues during the year under review , your directors has not recommended any divided for the financial year 2017-18.

2. SHARE CAPITAL:

During the year under review, Bal Pharma Limited has acquired 35,90,000 Equity Shares of Rs.10/- each constituting 100% of the paid up capital of the Company. With the said transaction, Golden Drugs Private Limited has become a wholly owned subsidiary of Bal Pharma Limited.

3. AUDITORS AND AUDITORS REPORT:

Messrs K. N & Associates, Chartered Accountants (Registration No.013495C) continues to be the statutory auditors of the Company for the financial year 2017.18.

There are no qualifications or reservations or adverse remarks by the auditors in their report issued for the financial year ended 31st March, 2018.

5.DIRECTORS' RESPONSIBILITY STATEMENT:

In compliance with the provisions of Section 134(5) of the Companies Act, 2013, your Directors wish to confirm with reference to Statement of Accounts for the financial year ended on 31st March, 2018:

- a) that in preparing the Annual Accounts, all the applicable Accounting Standards have been followed;
- b) that the Directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the Financial Year and of the Profit & Loss of the Company for that period.

c) that the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing/detecting fraud and other irregularities;

d) that the Directors have prepared the annual accounts on 'going concern basis.'

e) that the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and operating effectively.

f) that the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

6. CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES

All contracts/arrangements/transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on arm's length basis.

7. DIRECTORS AND KEY MANAGERIAL PERSONNEL AS ON 31.03.2018.

Mr. Chader Khamesara - Director
Mr. Ramesh Daglia - Director

Mrs.Snehalata Dalal has resigned from the Directorship of the Company w.e.f 22.03.2018.

8. VIGIL MECHANISM:

The vigil mechanism of the Company, which also incorporates a whistle blower policy. It includes compliance task force comprising of senior executives of the Company.

9. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND FOREIGN EXCHANGE OUTGO

There were no earnings or outgo of foreign exchange and other requirements pursuant to the Companies Act, 2013.

10. PARTICULARS OF EMPLOYEES

Referring to Section 197 of the Companies Act, 2013 and rule 5 (2) of the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014, none of the employees draw remuneration in excess of Rs.60.00 Lakhs per year or Rs.5.00 Lakh per month, if employed for the part of the year.

11. PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN OR SECURITY PROVIDED BY THE COMPANY:

Nil

12. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

There was no complaint lodged by any woman employee under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, with the Company during the period under report.

13. NUMBER OF MEETINGS OF THE BOARD OF DIRECTORS:

The Meetings of the Board are held at regular intervals with a time gap of not more than 120 days between two consecutive Meetings. During the financial year 2017-18 Six (06), Board Meeting were held on 5-June-17, 1-Sept-17, 14-Dec-17, 27-Dec-17, 17-Feb-18 and 22-March-2018.

14. HUMAN RESOURCES

Human Resource agenda of the company for the year to focus on building a talent pipeline, enhancing individual and organizational capabilities for future readiness, driving greater employee engagement, and strengthening employee relations through progressive people management.

15. INSURANCE COVERAGE

The Board of Directors reports that your Company has adequate and comprehensive insurance cover on all the movable and immovable assets of the Company as on 31.3.2018.

16. MATERIAL ORDER PASSED BY ANY COURT OR REGULATOR OR TRIBUNAL IMPACTING GOING CONCERN STATUS OF COMPANY:

Nil

17. CORPORATE SOCIAL RESPONSIBILITY:

Not Applicable.





Phone : 0294 2490411
Email : golden.drugs2012@gmail.com
Website : www.goldendrugs.in

Golden Drugs Private Limited

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Details relating to deposits covered under Chapter V of the Act.
2. Issue of equity shares with differential rights as to dividend, voting etc.
3. Issue of shares (including sweat equity shares) to the employees of the Company under any scheme.
4. No significant or material orders were passed by the regulators or courts or tribunals which impact the going concern status and Company's operations in the future.

29. APPRECIATION

Your Directors wish to express their sincere appreciation on significant contributions made by the employees through their dedication, hard work and commitment.

Place: Udalpur
Date :09.04.2018

For and on behalf of the Board of Directors

Chander Khamesara

Chander Khamesara
Director
DIN: 01946373

Ramesh Dagla

Ramesh Dagla
Director
DIN: 05353823



REGD. OFFICE : A-10, Main Industrial Area, Udalpur - 313003, Rajasthan
C-155, Main Market, Udalpur, Rajasthan 313003
CIN # U23203RJ2012PTC039907

Annexure-1

Form No. MGT-9

EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON 31st MARCH, 2018.
[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i.	CIN	U24232RJ2012PTC039907
ii.	Registration Date	27/08/2012
iii.	Name of the company	GOLDEN DRUGS PRIVATE LIMITED
iv.	Category/Sub Category of the Company	Company limited by shares and Indian Non-Government Company
v.	Registered Office Address	# C-155, Mewar Industrial Area Madri, Udaipur-313001, Rajasthan, India
vi.	City	Udaipur
Vii.	Whether Listed Company	No
Vii	Name, Address and contact details of Registrar and Transfer Agent, If any	

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sr.No	Name and description of main products/service	NIC code of the Product/service	% of the total turnover of the Company
1.	NA	NA	NA

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

Sr.No.	Name and Address of the Company	CIN	Holding/subsidiary % of shares held /Associate	Applicable Section
I.	Bal Pharma Limited	L85110KA1987PLC008368	Holding 99.72%	2(46)



IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% change during the year
	Dem at	Physical	Total	% of Total Shares	Dema t	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/HUF	-	35,90,000	35,90,000	100%	-	NIL	NIL	NIL	100%
b) Central Govt. or State Govt.	-	-	-	-	-	-	-	-	-
c) Bodies Corporates	-	-	-	-	-	-	-	-	-
d) Bank/FI	-	-	-	-	-	-	-	-	-
e) Any other	-	-	-	-	-	-	-	-	-
SUB TOTAL:(A) (1)	-	-	-	-	-	-	-	-	-
(2) Foreign									
a) NRI- Individuals	-	-	-	-	-	-	-	-	-
b) Other Individuals	-	-	-	-	-	-	-	-	-
c) Bodies Corp.	-	-	-	-	-	-	-	-	-
d) Banks/FI	-	-	-	-	-	-	-	-	-
e) Any other...	-	-	-	-	-	-	-	-	-
SUB TOTAL (A) (2)	-	-	-	-	-	-	-	-	-
Total Shareholding of Promoter	-	3,59,00,000	3,59,00,000	100%	-	-	-	-	-
(A)= (A)(1)+(A)(2)									
B. PUBLIC SHAREHOLDING									
(1) Institutions									
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks/FI	-	-	-	-	-	-	-	-	-
c) Cenntral govt	-	-	-	-	-	-	-	-	-
d) State Govt.	-	-	-	-	-	-	-	-	-
e) Venture Capital Fund	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIIS	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-




SUB TOTAL (B)(1):	-	-	-	-	-	-	-	-	-
(2) Non Institutions	-	-	-	-	-	-	-	-	-
a) Bodiescorporates	-	-	-	-	-	-	-	-	-
i) Indian	-	-	-	-	-	3,58,00,00	3,58,00,00	-	+99.72
ii) Overseas	-	-	-	-	-	-	-	-	-
b) Individuals	-	-	-	-	-	10000	10000	-	+0.28
i) Individual shareholders holding nominal share capital upto Rs.1 lakhs	-	-	-	-	-	-	-	-	-
ii) Individuals shareholders holding nominal share capital in excess of Rs. 1 lakhs	-	-	-	-	-	-	-	-	-
c) Others (specify)	-	-	-	-	-	-	-	-	-
SUB TOTAL (B)(2):	-	-	-	-	-	-	-	-	-
Total Public Shareholding (B)= (B)(1)+(B)(2)	-	-	-	-	-	-	-	-	-
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	-	35,90,000	35,90,000	100%	-	35,90,000	35,90,000	100%	100%

ii) Shareholding of Promoters:

Sl No.	Shareholders Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in share holding during the year
		No. of shares	% of total shares of the company	% of shares pledged encumbered to total shares	No. of shares	% of total shares of the company	% of shares pledged encumbered to total shares	
1.	Chander Khamesara	4,20,000	11.69%	-	NIL	NIL	NIL	-11.69%
2.	Ramesh Daglia	3,15,000	8.77%	-	NIL	NIL	NIL	-8.77%
3.	Sneh Lata Dalal	1,30,000	3.62%	-	NIL	NIL	NIL	-3.62%
4.	Bal Pharma Ltd	Nil	Nil	-	35,80,000	99.72	NIL	99.72%
5.	Shailesh Siroya	Nil	Nil	-	10,000	0.28	NIL	0.27%

iii) Changing in Promoters Shareholding (Specify if there is no change) :

Sl.	Particulars	Share holding at the beginning of the	Cumulative Share holding during the
-----	-------------	---------------------------------------	-------------------------------------




No.	Year	year			
		No. of Shares	% of total shares of the company	No of shares	% of total shares of the company
1.	At the beginning of the year	3,59,00,000	100%	3,59,00,000	100%
2.	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g.allotment/transfer/bonus/ sweat equity etc)	- 3,59,00,00 on 22.3.18. Due to 100% Sale of Shares to Bal Pharma Limited	100%	- 3,59,00,00 Due to 100% Sale of Shares to Bal Pharma Limited	100%
3.	At the end of the year	NIL	NIL	NIL	NIL

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters & Holders of GDRs & ADRs):

Sl. No	For Each of the Top 10 Shareholders	Reason	Shareholding at the end of the year		Cumulative Shareholding during the year	
			No.of shares	% of total shares of the company	No of shares	% of total shares of the company
1.	Bal Pharma Limited	At the Beginning of the Year	NIL	NIL	NIL	NIL
		Change	3,58,00,00	+99.72%	3,58,00,00	+99.72%
		At the End of the Year	3,58,00,00	+99.72%	3,58,00,00	+99.72%
2.	Mr. Shailesh D Siroya	At the Beginning of the Year	NIL	NIL	NIL	NIL
		Change	10000	0.28%	10000	0.28%
		At the End of the Year	+10000	+0.28%	+10000	+0.28%

(v) Shareholding of Directors & KMP

Sl. No	For Each of the Directors & KMP	Reason	Shareholding at the end of the year		Cumulative Shareholding during the year	
			No.of shares	% of total shares of the company	No.of shares	% of total shares of the company
1.	Mr. Chander Khamesra	At the Beginning of the Year	4,20,000	14.24%	4,20,000	14.24%
		Change	-4,20,000	-14.24%	-4,20,000	-14.24%
		At the End of the Year	NIL	NIL	NIL	NIL
2.	Mr. Ramesh Daglia	At the Beginning of the Year	3,15,000	10.68%	3,15,000	10.68%
		Change	-3,15,000	-10.68%	-3,15,000	-10.68%
		At the End of the Year	NIL	NIL	NIL	NIL
3.	Mrs.Snehalata Dalal	At the Beginning of the Year	130000	-3.62	130000	-3.62



Change	-130000	3.62%	130000	3.62%
At the End of the Year	Nil	Nil	Nil	Nil

V. INDEBTEDNESS:

Particulars	Secured Loan excluding deposits	Unsecured Loan	Deposits	Total Indebtedness in Inr.
Indebtedness at beginning of the financial year				
i).Principal Amount	-	-	-	-
ii).Interest due but not paid	-	-	-	-
iii).interest accrued but not due	-	-	-	-
Total(i+ii+iii)	-	-	-	-
Change in the Indebtedness during the financial year				
-Addition	-	5,59,05,158	-	5,59,05,158
-Reduction	-	-	-	-
Net Change	-	5,59,05,158	-	5,59,05,158
Indebtedness at the end of the financial year				
i).Principal Amount	-	5,59,05,158	-	5,59,05,158
ii).Interest due but not paid	-	-	-	-
iii).interest accrued but not due	-	-	-	-
Total(i+ii+iii)		5,59,05,158	-	5,59,05,158

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

A. Remuneration to Managing Director, Whole-Time Director:

Sl.No.	Particulars of Remuneration	Name of MD/WTD/Manager	Total Amount
1.	Gross Salary (a) salary as per provisions contain in Section 17(1) of Income tax Act 1961. (b) Valuation of Prequisites u/s 17(2) of Income tax Act 1961. (c) profit in lieu of Salary U/s 17(3) of Income tax Act 1961.	Nil	Nil




2.	Stock Option		
3.	Sweat equity		
4.	Commission		
	- as % of Profit:		
	-others, specify		
5	others		
6.	Total(A)		
	Ceiling as per the Act	NA	NA

B. Remuneration to other directors:

SI No	Particulars of Remuneration	Name of MD/WTD/Manager	Total Amount
	<u>Independent Directors</u>	NA	NA
	-Fee for attending the Board/Committees Meetings		
	-Commission		
	-Other		
	Total (1)		
	<u>Other Non-Executive Directors</u>		
	-Fee for attending the Board/Committees Meetings		
	-Commission		
	-Other		
	Total (2)		
	Total(B)=(1+2)		
	Total Managerial Remuneration		
	Overall Ceiling as per the Act		





Phone : 0294-2490411

Email : goldendrugs2012@gmail.com

Website : www.goldendrugs.in

Goldendrugs Private Limited
C. Remuneration to Key Managerial Personnel other than MD/Manager/WTD;

Sl.No.	Particular of Remuneration	Key Managerial Personnel			Total
		CEO	Company Secretary	CFO	
1.	Gross Salary (a) salary as per provisions contain in Section 17(1) of Income tax Act 1961. (b) Valuation of Perquisites u/s 17(2) of Income tax Act 1961. (c) profit in lieu of Salary U/s 17(3) of Income tax Act 1961.	NII	NII	NII	NII
2.	Stock Option				
3.	Sweat equity				
4.	Commission - as % of Profit				
	-others, specify				
5.	others				
6.	Total	NII	NII	NII	NII

VII. COMPOUNDING/PENALTIES/PUNISHMENT OF OFFENCES:

NII

Place: Udaipur

Date : 09.04.2018

For and on behalf of the Board of Directors

Chander Khamesara

Chander Khamesara

Director

DIN: 01946373

Ramesh Daglla

Ramesh Daglla

Director

DIN: 05353823



REGD OFFICE : # C-115, Mower Industrial Area, Madri, Udaipur - 313001, Rajasthan

C-155, NIA, Madri, Udaipur, Rajasthan - 313003

www.goldendrugs.in

GOLDEN DRUGS PRIVATE LIMITED

9, NEW FATEHPURA, UDAIPUR, RAJASTHAN

BALANCE SHEET AS AT 31ST MARCH, 2018

Particulars	Notes No.	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
I. EQUITY AND LIABILITIES			
<u>(1) Shareholder's Funds</u>			
(a) Share Capital	1	3,59,00,000	3,59,00,000
(b) Reserves and Surplus	2	-16,950	-34,78,068
(c) Money received against share warrants		-	-
<u>(2) Share Application money pending allotment</u>			
<u>(3) Non-Current Liabilities</u>			
(a) Long-Term Borrowings	3	5,59,05,158	5,28,83,594
(b) Deferred Tax Liabilities (Net)		-	-
(c) Other Long Term Liabilities		-	-
(d) Long Term Provisions		-	-
<u>(4) Current Liabilities</u>			
(a) Short-Term Borrowings		-	-
(b) Trade Payables		-	-
(c) Other Current Liabilities	4	6,72,795	19,85,711
(d) Short-Term Provisions		-	-
Total Equity & Liabilities		9,24,61,003	8,72,91,237
II. ASSETS			
<u>(1) Non-Current Assets</u>			
<u>(a) Fixed Assets</u>			
(i) Gross Block	5	9,13,12,250	8,22,17,501
(ii) Depreciation		-	-
(iii) Net Block		9,13,12,250	8,22,17,501
(b) Non-current investments		-	-
(c) Deferred tax assets (net)		-	-
(d) Long term loans and advances		-	-
(e) Other non-current assets		-	-
<u>(2) Current Assets</u>			
(a) Current investments		-	-
(b) Inventories		-	-
(c) Trade receivables		-	-
(d) Cash and cash equivalents	6	5,59,293	3,28,947
(e) Short-term loans and advances	7	5,89,460	47,44,789
(f) Other current assets		-	-
Total Assets		9,24,61,003	8,72,91,237

NOTES TO ACCOUNTS

8

Notes referred to above and notes attached there to form an integral part of Balance Sheet

This is the Balance Sheet referred to in our Report of even date.

FOR K N & ASSOCIATES

CHARTERED ACCOUNTANTS

(Signature)

CA. NIRMAL KUNAWAT
PROPRIETOR

Membership no. 073765



FOR GOLDEN DRUGS PRIVATE LIMITED

(Signature)

(DIRECTOR)

(Signature)

(DIRECTOR)

PLACE: UDAIPUR
DATED: 09/04/2018

GOLDEN DRUGS PRIVATE LIMITED
9, NEW FATEHPURA, UDAIPUR, RAJASTHAN
PROFIT & LOSS STATEMENT FOR THE PERIOD ENDED ON 31ST March, 2018

Sr. No	Particulars	Notes No.	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
I	Revenue from operations		-	-
II	Other Income		-	-
III	III. Total Revenue (I +II)		0	0
IV	<u>Expenses:</u>			
	Cost of materials consumed			
	Purchase of Stock-in-Trade			
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade			
	Employee Benefit Expense			
	Financial Costs			-
	Depreciation and Amortization Expense			-
	Other Administrative Expenses			-
	Total Expenses (IV)		-	-
V	Profit before exceptional and extraordinary items and tax	(III - IV)	0	0
VI	Exceptional Items		-	-
VII	Profit before extraordinary items and tax (V - VI)		0	0
VIII	Extraordinary Items		-	-
IX	Profit before tax (VII - VIII)		0	0
X	<u>Tax expense:</u>			
	(1) Current tax		-	-
	(2) Deferred tax		-	-
XI	Profit(Loss) from the period from continuing operations	(IX-X)	0	0
XII	Profit/(Loss) from discontinuing operations		-	-
XIII	Tax expense of discounting operations		-	-
XIV	Profit/(Loss) from Discontinuing operations (XII - XIII)		0	0
XV	Profit/(Loss) for the period (XI + XIV)		0	0
XVI	Earning per equity share:			
	(1) Basic		-	-
	(2) Diluted		-	-

Notes referred to above and notes attached there to form an integral part of Profit & Loss Statement

8

This is the Profit & Loss Statement referred to in our Report of even date.

FOR K N & ASSOCIATES

CHARTERED ACCOUNTANTS


CA. NIRMAL KUNAWAT
PROPRIETOR
Membership no. 073765



FOR GOLDEN DRUGS PRIVATE LIMITED

 
(DIRECTOR) (DIRECTOR)

PLACE: UDAIPUR
DATED: 09/04/2018

GOLDEN DRUGS PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2018

Note no. 1 Share Capital

Sr. No	Particulars	Current year	Previous year
1	AUTHORIZED CAPITAL 4500000 Equity share (Previous year 4500000 equity shares) of Rs. 10 each	4,50,00,000	4,50,00,000
		4,50,00,000	4,50,00,000
2	ISSUED, SUBSCRIBED & PAID UP CAPITAL <i>To the Subscribers of the Memorandum</i> 3590000 Equity Shares (Previous year 3590000 Equity shares) of Rs. 10 each fully paid up	3,59,00,000	3,59,00,000
	Total	3,59,00,000	3,59,00,000

Note no. 1.1 Details of share holder holding more than 5% shares:-

Sr. No	Name of Share holders	Current year		Previous year	
		No. of shares	% held	No. of shares	% held
1	Chander Khamesara (HUF)	0	0.00%	225000	6.27%
2	Chander Khamesara	0	0.00%	420000	11.70%
3	Gulshan Dalal Jain	0	0.00%	404600	11.27%
4	Ramesh Daglia	0	0.00%	315000	8.77%
5	Suman Daglia	0	0.00%	185000	5.15%
6	Vinod Kumar Dalal	0	0.00%	200000	5.57%
7	Bal Pharma Ltd	3580000	99.72%	0	0.00%

Note No. 2 Reserve & Surplus

Sr. No	Particulars	Current year	Previous year
1	Preliminary expenditure	-16,950	-16,950
	Opening Balance	-16,950	-16,950
2	Preoperative expenditure	0	-34,61,118
	Opening Balance	-34,61,118	-32,33,566
	Add: during the year		
	Audit Remuneration	0	-30,000
	Bank Charges	-8,481	-40,474
	Environmental Clearing Expense	0	-73,000
	Annual Charges (RIICO)	-65,339	-59,112
	Interest paid on TDS	0	-966
	Salary/wages	0	-24,000
	Less: Transfer to Plant and Machinery, Electrical Installation and building construction proportionately	35,34,938	0
	Total	-16,950	-34,78,068

Note No. 3 Long Term Liabilities

Sr. No	Particulars	Current year	Previous year
1	Secured Loan		
	PNB Term Loan	-	29514594
	Total	0	29514594
	Unsecured Loan		
1	Chander Khamesra	-	60,50,000
2	Dal Chand Daglia	-	11,10,000
3	Bal Pharma Ltd.	5,59,05,158	-
4	Ramesh Daglia	-	7,55,000
5	Sanil khamesra	-	5,00,000
6	Sonal Khamesara	-	30,00,000
7	Sneh lata Dalal	-	72,54,000
8	Mayura Jewels India pvt Ltd	-	47,00,000
	Total	5,59,05,158	2,33,69,000
	Total	5,59,05,158	5,28,83,594



MAYURA JEWELS INDIA PVT. LTD.

DIRECTOR

GOLDEN DRUGS PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2018

Note No. 4 Other Current Liabilities

Sr. No	Particulars	Current year	Previous year
1	K N & Associates	-	1,00,000
2	Ajanta Paints and Hardware	-	2,84,827
3	Clean Air Engineer,	4,45,297	2,54,205
4	Explore Watek System pvt Ltd	2,27,498	2,27,498
5	Hyltech Sweet Water Tech Pvt Ltd	-	43,700
6	Jay Instruments	-	1,25,563
7	Kunawat & Associates	-	10,000
8	Machine Well	-	7,46,290
9	Mahalaxmi Metal	-	32,428
10	Motuba Wires & Cables	-	4,200
11	Vikas Maheshwari	-	96,000
12	Excise Consultancy Services	-	12,000
13	R L Kunawat & Co.	-	13,000
14	MR Associates	-	36,000
	Total	6,72,795	19,85,711



~~MAYURA JEWELS IN A PVT. LTD.~~
[Handwritten signature]

DIRECTOR

GOLDEN DRUGS PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2018

Note : 5 Fixed Asset

Sr. No	Particulars	Gross Block			Depreciation			Net Block		
		Value at the beginning	Addition during the year	Deduction during the year	Value at the end	Value at the beginning	Addition during the year	Deduction during the year	Value at the end	WDV as on 31.03.2017
I	<u>Tangible Assets</u>									
1	Land	1,50,00,000	-	-	1,50,00,000	-	-	-	15000000	15000000
2	Plant & Machinery	5,67,94,428	85,84,681	-	6,53,79,109	-	-	-	65379109	56794428
3	Electric Installation	47,85,886	2,34,204	-	50,20,090	-	-	-	5020090	4785886
	SUB TOTAL (A)	7,65,80,314	88,18,885	-	8,53,99,199	-	-	-	8,53,99,199	7,65,80,314
III	<u>Capital Work-in-progress</u>									
1	Building Under Construction	56,37,187	2,75,864	-	59,13,051	-	-	-	59,13,051	56,37,187
	SUB TOTAL (C)	56,37,187	2,75,864	-	59,13,051	-	-	-	59,13,051	56,37,187
	Total [A + B + C + D] (Current Year)	8,22,17,501	90,94,749	-	9,13,12,250	-	-	-	9,13,12,250	8,22,17,501
	(Previous Year)	7,80,74,587	41,80,578	37,664	8,22,17,501	-	-	-	8,22,17,501	7,69,30,347

(Signature)



DIRECTOR

GOLDEN DRUGS PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2018

Note no. 6 Cash & Cash Equivalent

Sr. No	Particulars	Current year	Previous year
1	ICICI Bank	1037	173855
2	PNB Bank	500005	12573
3	Cash in Hand	58251	142519
	Total	5,59,293	3,28,947

Note :7 Short Terms Loans and Advances

Sr. No	Particulars	Current year	Previous year
	<u>Duties and Taxes</u>		
1	Excise Input Credit receivable	-	25,34,529
2	Excise 12.5%	-	2,98,135
3	Excise Duty	-	98,598
4	VAT Input receivable	5,89,460	5,93,049
	Total	5,89,460	35,24,311
	<u>Advance To Suppliers</u>		
1	A to Z Sheet Metal	-	868499
2	Raheja Infotech	-	343129
3	Kanti Lal Chiman Lal Ahemdabad	-	8850
	Total	0	1220478
	Total	5,89,460	47,44,789

Handwritten signature

Handwritten signature
DIRECTOR



GOLDEN DRUGS PRIVATE LIMITED

Notes Forming Part of the Profit & Loss Accounts as at 31st march,2018

Note no.8 NOTES ON ACCOUNTS

- 1 STATEMENT OF SIGNIFICANT ACCOUNTING POLICES :-
 - A) The Accounts are prepared under the historical cost convention unless otherwise stated and generally on the accrual method of accounting.
 - B) Accounting Policies not stated explicitly otherwise are consistent with generally accepted accounting principles.
- 2 CONTINGENT LIABILITIES :-
 - A) There are no contingent liabilities which can affect the state of affairs of the Company.
- 3 I. There has been no inflow / outflow of Foreign Exchange.

II. The figures of the previous year have been regrouped / rearranged wherever considered necessary.

The Company has not started business during the period under reference but Profit & Loss Account has been prepared at NIL Profit/Loss. The expenditure including term loan interest incurred during the period under reference and the pre operative expenditure have been capitalised under the head Plant and Machinery, Electrical installation and Building under construction in the proportion of their book value.
- 4
- 5 Balances of Sundry Creditors, Unsecured Loan, Loan & Advances and sundry Debtors, if any are subject to confirmation and taken from books of accounts only.

NOTES "1" TO "8" ANNEXED TO AND FORMING PART OF ACCOUNTS AS ON 31/03/2018

Notes attached there to form an integral part of Balance Sheet
This is the Balance Sheet referred to in our Report of even date.

FOR K N & ASSOCIATES
CHARTERED ACCOUNTANTS


NIRMAL KUNAWAT
PROPRIETOR
Membership No. : 073765



FOR GOLDEN DRUGS PRIVATE LIMITED


(DIRECTOR)


(DIRECTOR)

PLACE: UDAIPUR
DATED: 09/04/2018